Clinical decision-making in hereditary angioedema (HAE) management involves a high
degree of complexity given the number of therapeutic agents that are available and the risk …

Background Hereditary angioedema (HAE), a rare disease that is characterized by painful
and recurring non‐allergic swelling episodes, is caused by the deficiency or dysfunction of …

Background: A diagnosis of hereditary angioedema (HAE) with normal C1 esterase inhibitor
(HAE-nl-C1-INH) can be challenging and pharmacologic management is not well defined …

Hereditary Angioedema (HAE) is a potentially life-threatening condition. With episodic,
unpredictable swelling, HAE negatively affect the quality of life for those affected individuals …

Hereditary angioedema (HAE) is typically caused by a deficiency of the protease inhibitor
C1 inhibitor (C1INH). The absence of C1INH activity on plasma kallikrein and factor XIIa …

Background Hereditary angioedema (HAE) is a rare disease characterized by recurrent
attacks of severe swellings of the skin and submucosa. More than 900 variants of the …

The complement system is an essential component of the innate immune response and
plays a vital role in host defense and inflammation. Dysregulation of the complement system …

Hereditary angioedema (HAE) is a severe and disabling condition characterized by
recurrent episodes of subcutaneous or mucosal swelling in the skin, respiratory and …

Background: Hereditary angioedema (HAE) is a rare genetic disorder characterized by
recurrent, localized episodes of edema. Current treatment guidelines highlight the …

Background Hereditary angioedema (HAE) is a rare and potentially fatal genetic disease
associated with recurrent and unpredictable episodes of angioedema. Although modern …